About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 1 Study of Quizartinib | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT02675478

Phase 1 Study of Quizartinib

This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.

Lead sponsor: Daiichi Sankyo Co., Ltd.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Daiichi Sankyo Co., Ltd.

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Relapsed or refractory AML
•AML for which no standard treatment is available
•ECOG Performance Status (PS) of 0 to 2

Exclusion Criteria

•Acute Promyelocytic Leukemia
•chronic myelogenous leukemia in blast phase (BCR-ABL fusion gene positive)
•History of other malignancies within 3 years prior to enrollment, except curatively treated in-situ carcinoma, AML, or MDS.

Related studies

RECRUITINGPhase 1

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

NCT06307054 · Relapsed Adult AML, Refractory AML

RECRUITINGPhase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

NCT06022003 · AML, Adult, Refractory AML, and more

Active Not RecruitingPhase 1/2

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

NCT05428969 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and more

Active Not RecruitingPhase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002 · Relapsed / Refractory AML, Relapsed / Refractory MDS

Active Not RecruitingPhase 1

CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476 · Relapsed AML, Refractory AML

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 12, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment17

Start dateFeb 2016

Last updatedFeb 12, 2019

Condition

Relapsed AML Refractory AML

Locations shown

Tokyo

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2019Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions